

# Protocol

## Genotype-Guided Warfarin Dose

(20448)

(Formerly Genetic Testing for Warfarin Dose)

<b>Medical Benefit</b>		<b>Effective Date:</b> 04/01/19	<b>Next Review Date:</b> 01/20
<b>Preauthorization</b>	No	<b>Review Dates:</b> 01/11, 01/12, 01/13, 01/14, 01/15, 01/16, 01/17, 01/18, 01/19	

***This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.***

*The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.*

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"><li>• With conditions requiring warfarin treatment</li></ul>	Interventions of interest are: <ul style="list-style-type: none"><li>• Genotype-guided warfarin dosing</li></ul>	Comparators of interest are: <ul style="list-style-type: none"><li>• Clinically guided warfarin dosing</li></ul>	Relevant outcomes include: <ul style="list-style-type: none"><li>• Morbid events</li><li>• Medication use</li><li>• Treatment-related mortality</li><li>• Treatment-related morbidity</li></ul>

### DESCRIPTION

Using information about an individual's genotypes may help in guiding warfarin dosing and could reduce the time to dose stabilization and selection of an appropriate maintenance dose that might avoid the consequences of too much or too little anticoagulation.

### SUMMARY OF EVIDENCE

For individuals with conditions requiring warfarin treatment who receive genotype-guided warfarin dosing, the evidence includes multiple randomized controlled trials (RCTs) and systematic reviews of the RCTs. Relevant outcomes are morbid events, medication use, and treatment-related mortality and morbidity. Fourteen RCTs were identified. While five of the 14 RCTs reported statistically significant differences in outcomes related to the international normalized ratio, none of the trials or pooled meta-analyses of the trials have shown a benefit for outcomes of major bleeding or venous thromboembolism. In the pooled analysis including 2223 participants, 87 events of the composite outcome (mortality, major bleed, and thromboembolic events) occurred (relative risk, 0.85; 95% confidence interval, 0.54 to 1.34;  $p=0.48$ ). In the Genetics Informatics Trial (GIFT), which included 1650 participants, conducted after the pooled analysis, two versus eight major bleeding events occurred (relative risk, 0.24; 95% confidence interval, 0.05 to 1.15), 33 versus 38 venous thromboembolism events occurred (relative risk, 0.85; 95% confidence interval, 0.54 to 1.34), and there were no deaths. Very few trials have enrolled sufficient numbers of subpopulations except white participants. In the Clarification of Optimal Anticoagulation through Genetics (COAG) study, which included 27% African American participants, African Americans fared

better in the clinically guided group than in the genotype-guided group. The evidence is insufficient to determine the effects of the technology on health outcomes.

## POLICY

Genotyping to determine cytochrome p450 2C9 (CYP2C9), P450 4F2 (CYP4F2), and vitamin K epoxide reductase subunit C1 (VKORC1) genetic variants is considered **investigational** for the purpose of managing the administration and dosing of warfarin, including use in guiding the initial warfarin dose to decrease time to stable international normalized ratio and reduce the risk of serious bleeding.

## POLICY GUIDELINES

### GENETICS NOMENCLATURE UPDATE

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical protocol updates starting in 2017 (see Table PG1). The Society's nomenclature is recommended by the Human Variome Project, the HUMAN Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—"pathogenic," "likely pathogenic," "uncertain significance," "likely benign," and "benign"—to describe variants identified that cause Mendelian disorders.

Table PG1. Nomenclature to Report on Variants Found in DNA

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely Pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

### Genetic Counseling

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

## MEDICARE ADVANTAGE

For Medicare Advantage there may be potential for benefit under coverage with evidence development (CED) when the members are candidates for anticoagulation therapy with warfarin who:

1. Have not been previously tested for CYP2C9 or VKORC1 alleles; and
2. Have received fewer than five days of WARFARIN in the anticoagulation regimen for which the testing is ordered; and
3. Are enrolled in a prospective, randomized, controlled clinical study when that study meets CMS standards.

For Medicare Advantage the available evidence does not demonstrate that pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness improves health outcomes outside the context of CED, and is therefore **not medically necessary**.

## BACKGROUND

Warfarin is administered to prevent and treat thromboembolic events in high-risk patients; warfarin dosing is a challenging process, due to the narrow therapeutic window, variable response to dosing, and serious bleeding events in 5% or more of patients (depending on definition). Patients are typically given a starting dose of two to five mg and frequently monitored with dose adjustments until a stable international normalized ratio value (a standardized indicator of clotting time) between two and three is achieved. During this adjustment period, a patient is at high risk of bleeding.

Stable or maintenance warfarin dose varies among patients by more than an order of magnitude. Factors influencing stable dose include body mass index, age, interacting drugs, and indication for therapy.

Warfarin, which is primarily metabolized in the liver by the CYP2C9 enzyme, exerts an anticoagulant effect by inhibiting the protein vitamin K epoxide reductase complex, subunit 1 (VKORC1). Three single nucleotide variants, two in the CYP2C9 gene and one in the VKORC1 gene play key roles in determining the effect of warfarin therapy on coagulation.<sup>1-10</sup> CYP2C9\*1 metabolizes warfarin normally, CYP2C9\*2 reduces warfarin metabolism by 30%, and CYP2C9\*3 reduces warfarin metabolism by 90%. Because warfarin given to patients with \*2 or \*3 variants will be metabolized less efficiently, the drug will remain in circulation longer, so lower warfarin doses will be needed to achieve anticoagulation. CYP2C9 and VKORC1 genetic variants account for approximately 55% of the variability in warfarin maintenance dose.<sup>1,11</sup> Recent genome-wide association studies have also identified that a single nucleotide variant in the CYP4F2 gene has been reported to account for a small proportion of the variability in stable dose (the CYP4F2 gene encodes a protein involved in vitamin K oxidation).<sup>12,13</sup> Studies have predicted that CYP4F2 variants explain 2% to 7% of the variability in warfarin dose in models, including other genetic and nongenetic factors.<sup>13,14</sup>

Using the results of CYP2C9 and VKORC1 genetic testing to predict a warfarin starting dose that approximates a likely maintenance dose may benefit patients by decreasing the risk of serious bleeding events and the time to stable international normalized ratio. Algorithms have incorporated not only genetic variation but also other significant patient characteristics and clinical factors to predict the best starting dose.<sup>2,15-21</sup> Studies have compared the ability of different algorithms to predict stable warfarin dose accurately.<sup>22-26</sup> Currently, there does not appear to be consensus for a single algorithm.<sup>25</sup>

Several studies have examined associations between CYP2C9 and VKORC1 variants and warfarin dosing requirements in children.<sup>27-29</sup>

There are different frequencies of variants related to warfarin pharmacokinetics across different races and ethnicities. Many of the original studies identifying associations between genes and prediction of warfarin dosing as well as studies developing algorithms were derived from cohorts composed largely of people of European

descent. Evidence has suggested these algorithms do not perform as well in other ethnic groups.<sup>16-18,30</sup> For example, CYP2C9\*2 and CYP2C9\*3 are not as useful in predicting warfarin dosing in African Americans, but other important variants have been identified such as CYP2C9\*5, \*6, \*8, and \*11.<sup>31</sup> Studies have also identified new genetic variants and/or evaluated clinical genetic algorithms for warfarin dose in African American,<sup>32-34</sup> Puerto Rican,<sup>35</sup> Thai,<sup>36</sup> Egyptian,<sup>37,38</sup> Chinese,<sup>39-41</sup> Japanese,<sup>42</sup> Arabic,<sup>43</sup> Turkish,<sup>44</sup> and Scandinavian<sup>45</sup> populations.

## REGULATORY STATUS

Several tests to help assess warfarin sensitivity, by determining the presence or absence of the relevant CYP2C9, VKORC1, and CYP4F2 variants, have been cleared by the U.S. Food and Drug Administration (FDA) for marketing (see Table 1). Similar tests also may be available as laboratory-developed services; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). The tests are not identical regarding the specific variants and number of variants detected. Generally, such tests are not intended as stand-alone tools to determine optimum drug dosage but should be used with clinical evaluation and other tools, including the international normalized ratio, to predict the initial dose that best approximates the maintenance dose for patients.

Table 1. FDA-Cleared Warfarin Tests

Test (Laboratories)	Alleles Tested	Estimated Time to Completion, h
eSensor® Warfarin Sensitivity Test (GenMark Dx, <sup>a</sup> )	CYP2C9*2 and *3, VKORC1 1639G>A	Three to four
Rapid Genotyping Assay (ParagonDx)	CYP2C9*2 and *3, VKORC1 1173 C>T	Not reported <sup>b</sup>
Verigene® Warfarin Metabolism Nucleic Acid Test (Nanosphere)	CYP2C9*2 and *3, VKORC1 1173 C>T	Two or less
Infiniti® 2C9-VKORC1 Multiplex Assay for Warfarin (AutoGenomics) <sup>c</sup>	CYP2C9*2 and *3, VKORC1 1639G>A	Six to eight
eQ-PCR™ LightCycler® Warfarin Genotyping Kit (TrimGen)	CYP2C9*2 and *3, VKORC1 1639G>A	Two or less

Adapted from Cavallari et al (2011). [46]

FDA: Food and Drug Administration.

<sup>a</sup> eSensor Warfarin Plus Test offers testing for CYP2C9\*2, \*3, \*5, \*6, \*11, \*14, \*15, and \*16, VKORC1 1639G>A, and CYP4F2.

<sup>b</sup> Langley et al (2009) reported a turnaround time of 1.5 hours for the ParagonDx SmartCycler, which may be a precursor assay.[22]

<sup>c</sup> The expanded Infiniti CYP450 2C9 assay offers testing for CYP2C9\*2, \*3, \*4, \*5, \*6, and \*11, VKORC1 1639G>A, and 6 other VKORC1 variants.

In 2007, FDA approved updated labeling for Coumadin® to include information on testing for gene variants that may help “personalize” the starting dose for each patient and reduce the number of serious bleeding events. The label was updated again in 2010. With each update, manufacturers of warfarin (Coumadin®) were directed to add similar information to their product labels. The 2010 update added information on guiding initial dose by genotyping results for CYP2C9 and VKORC1, providing a table of genotypes, and suggested initial dose ranges for each. However, suggested starting doses are also provided when genotyping information is unavailable, indicating that genetic testing is not required. Furthermore, FDA did not include information on genetic variation in the label’s black box warning on bleeding risk.

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

## REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. *Pharmacogenomics J*. 2005;5(4):262-270. PMID 15883587
2. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. *Hum Genet*. Mar 2007;121(1):23-34. PMID 17048007
3. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. *Blood*. Jan 22 2009;113(4):784-792. PMID 18574025
4. Gage BF, Eby C, Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. *Thromb Haemost*. Jan 2004;91(1):87-94. PMID 14691573
5. Hillman MA, Wilke RA, Caldwell MD, et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. *Pharmacogenetics*. Aug 2004;14(8):539-547. PMID 15284536
6. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. *Trends Pharmacol Sci*. Jul 2009;30(7):375-386. PMID 19540002
7. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. *N Engl J Med*. Jun 2 2005;352(22):2285-2293. PMID 15930419
8. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. *Hum Mol Genet*. Jul 1 2005;14(13):1745-1751. PMID 15888487
9. Geisen C, Watzka M, Sittlinger K, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnic variability of oral anticoagulation. *Thromb Haemost*. Oct 2005;94(4):773-779. PMID 16270629
10. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. *Blood*. Jan 15 2005;105(2):645-649. PMID 15358623
11. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. *Blood*. Oct 1 2005;106(7):2329-2333. PMID 15947090
12. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. *PLoS Genet*. Mar 2009;5(3):e1000433. PMID 19300499
13. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. *Blood*. Apr 15 2008;111(8):4106-4112. PMID 18250228
14. Borgiani P, Ciccacci C, Forte V, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. *Pharmacogenomics*. Feb 2009;10(2):261-266. PMID 19207028
15. Zhu Y, Shennan M, Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. *Clin Chem*. Jul 2007;53(7):1199-1205. PMID 17510308
16. Schelleman H, Chen J, Chen Z, et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. *Clin Pharmacol Ther*. Sep 2008;84(3):332-339. PMID 18596683
17. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. *Clin Pharmacol Ther*. Sep 2008;84(3):326-331. PMID 18305455

18. Wu AH, Wang P, Smith A, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. *Pharmacogenomics*. Feb 2008;9(2):169-178. PMID 18370846
19. Hatch E, Wynne H, Avery P, et al. Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients. *J Thromb Haemost*. Jun 2008;6(6):1038-1040. PMID 18419746
20. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. *Clin Pharmacol Ther*. May 2010;87(5):572-578. PMID 20375999
21. Wells PS, Majeed H, Kasseh S, et al. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. *Thromb Res*. Jun 2010;125(6):e259-264. PMID 20421126
22. Langley MR, Booker JK, Evans JP, et al. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. *J Mol Diagn*. May 2009;11(3):216-225. PMID 19324988
23. Shaw PB, Donovan JL, Tran MT, et al. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. *J Thromb Thrombolysis*. Aug 2010;30(2):220-225. PMID 20204461
24. Lubitz SA, Scott SA, Rothlauf EB, et al. Comparative performance of gene-based warfarin dosing algorithms in a multi-ethnic population. *J Thromb Haemost*. May 2010;8(5):1018-1026. PMID 20128861
25. Roper N, Storer B, Bona R, et al. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. *J Mol Diagn*. May 2010;12(3):283-291. PMID 20228265
26. Zambon CF, Pengo V, Padrini R, et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. *Pharmacogenomics*. Jan 2011;12(1):15-25. PMID 21174619
27. Hamberg AK, Wadelius M. Pharmacogenetics-based warfarin dosing in children. *Pharmacogenomics*. Feb 2014;15(3):361-374. PMID 24533715
28. Hawcutt DB, Ghani AA, Sutton L, et al. Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. *Pharmacogenomics J*. Dec 2014;14(6):542-548. PMID 25001883
29. Vear SI, Ayers GD, Van Driest SL, et al. The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. *Br J Haematol*. Jun 2014;165(6):832-835. PMID 24601977
30. Cavallari LH, Momary KM, Patel SR, et al. Pharmacogenomics of warfarin dose requirements in Hispanics. *Blood Cells Mol Dis*. Feb 15 2011;46(2):147-150. PMID 21185752
31. Kaye JB, Schultz LE, Steiner HE, et al. Warfarin pharmacogenomics in diverse populations. *Pharmacotherapy*. Sep 2017;37(9):1150-1163. PMID 28672100
32. Perera MA, Gamazon E, Cavallari LH, et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. *Clin Pharmacol Ther*. Mar 2011; 89(3):408-415. PMID 21270790
33. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. *Lancet*. Aug 31 2013;382(9894):790-796. PMID 23755828
34. Ramirez AH, Shi Y, Schildcrout JS, et al. Predicting warfarin dosage in European-Americans and African Americans using DNA samples linked to an electronic health record. *Pharmacogenomics*. Mar 2012;13(4): 407-418. PMID 22329724
35. Valentin II, Vazquez J, Rivera-Miranda G, et al. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. *Ann Pharmacother*. Feb 2012;46(2):208-218. PMID 22274142
36. Sangviroon A, Panomvana D, Tassaneeyakul W, et al. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin. *Drug Metab Pharmacokinet*. Oct 2010;25(6):531-538. PMID 20930419

37. Shahin MH, Khalifa SI, Gong Y, et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. *Pharmacogenet Genomics*. Mar 2011;21(3):130-135. PMID 21228733
38. Bazan NS, Sabry NA, Rizk A, et al. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients. *Int J Clin Pharm*. Dec 2012;34(6):837-844. PMID 22851439
39. You JH, Wong RS, Waye MM, et al. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. *J Thromb Thrombolysis*. Jan 2011;31(1):113-118. PMID 20585834
40. Ma C, Zhang Y, Xu Q, et al. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. *Int J Hematol*. Dec 2012;96(6):719-728. PMID 23104259
41. Xu Q, Xu B, Zhang Y, et al. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation. *Thromb Haemost*. Dec 2012;108(6):1132-1140. PMID 23015069
42. Aomori T, Obayashi K, Fujita Y, et al. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose. *Pharmazie*. Mar 2011;66(3):222-225. PMID 21553655
43. Alzahrani AM, Ragia G, Hanieh H, et al. Genotyping of CYP2C9 and VKORC1 in the Arabic population of AlAhsa, Saudi Arabia. *Biomed Res Int*. Apr 2013;2013:315980. PMID 23586031
44. Ozer M, Demirci Y, Hizel C, et al. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. *Basic Clin Pharmacol Toxicol*. Mar 2013;112(3):209-214. PMID 23061746
45. Skov J, Bladbjerg EM, Leppin A, et al. The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. *Thromb Res*. Feb 2013;131(2):125-129. PMID 23159229
46. Cavallari LH, Shin J, Perera MA. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. *Pharmacotherapy*. Dec 2011;31(12):1192-1207. PMID 22122181
47. Stergiopoulos K, Brown DL. Genotype-guided vs. clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. *JAMA Intern Med*. Aug 2014;174(8):1330-1338. PMID 24935087
48. Franchini M, Mengoli C, Cruciani M, et al. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. *J Thromb Haemost*. Sep 2014;12(9):1480-1487. PMID 25040440
49. Goulding R, Dawes D, Price M, et al. Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials. *Br J Clin Pharmacol*. Oct 2015;80(4):868-877. PMID 25060532
50. Liao Z, Feng S, Ling P, et al. Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing. *J Thromb Thrombolysis*. Feb 2015;39(2):228-234. PMID 24962733
51. Belley-Cote EP, Hanif H, D'Aragon F, et al. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis. *Thromb Haemost*. Oct 2015;114(4):768-777. PMID 26158747
52. Hillman MA, Wilke RA, Yale SH, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. *Clin Med Res*. Aug 2005;3(3):137-145. PMID 16160068
53. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. *Circulation*. Nov 27 2007;116(22):2563-2570. PMID 17989110
54. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. *Clin Pharmacol Ther*. Mar 2008;83(3):460-470. PMID 17851566
55. Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on inter-individual warfarin maintenance dose: a prospective study in Chinese patients. *Pharmacogenet Genomics*. Mar 2009;19(3):226-234. PMID 19177029
56. Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based Coumadin initiation. *Genet Med*. Jun 2011;13(6):509-518. PMID 21423021

57. Borgman MP, Pendleton RC, McMillin GA, et al. Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. *Thromb Haemost.* Sep 2012;108(3):561-569. PMID 22836303
58. Wang M, Lang X, Cui S, et al. Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial. *Int J Med Sci.* Aug 2012;9(6):472-479. PMID 22927772
59. Radhakrishnan AV, D.; Tayur, S.; et al. Genotype Guided Therapeutic Dosing of Warfarin in Geriatric Patients. *J Am Coll Cardiol.* 2012;59:E1696. PMID
60. Jonas DE, Evans JP, McLeod HL, et al. Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. *Pharmacogenomics.* Oct 2013;14(13):1593-1603. PMID 24088130
61. Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. *N Engl J Med.* Dec 12 2013;369(24):2283-2293. PMID 24251361
62. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. *N Engl J Med.* Dec 12 2013;369(24):2294-2303. PMID 24251363
63. Verhoef TI, Ragia G, de Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. *N Engl J Med.* Dec 12 2013;369(24):2304-2312. PMID 24251360
64. Pengo V, Zambon CF, Fogar P, et al. A randomized trial of pharmacogenetic warfarin dosing in naive patients with non-valvular atrial fibrillation. *PLoS One.* Dec 2015;10(12):e0145318. PMID 26710337
65. Gage BF, Bass AR, Lin H, et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT Randomized Clinical Trial. *JAMA.* Sep 26 2017;318(12):1115-1124. PMID 28973620
66. Makar-Aušperger K, Krzelj K, Lovric Bencic M, et al. Warfarin dosing according to the genotype-guided algorithm is most beneficial in patients with atrial fibrillation: a randomized parallel group trial. *Ther Drug Monit.* Feb 27 2018. PMID 29494423
67. Flockhart DA, O'Kane D, Williams MS, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. *Genet Med.* Feb 2008;10(2):139-150. PMID 18281922
68. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* Feb 2012;141(2 Suppl):7S-47S. PMID 22315257
69. Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. *Clin Pharmacol Ther.* Sep 2017;102(3):397-404. PMID 28198005
70. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Pharmacogenomic Testing for Warfarin Response (90.1). 2009; <https://www.cms.gov/medicare-coverage-database/details/ncddetails.aspx?NCDId=333&ncdver=1&bc=AgAAQAAAAAAAAAA%3d%3d&>. Accessed May 15, 2018.
71. National Coverage Determination (NCD) for Pharmacogenomic Testing for WARFARIN Response (90.1), Implementation Date 4/5/2010.
72. National Government Services, Inc. (Primary Geographic Jurisdiction 06 & K - Illinois, Minnesota, Wisconsin, Connecticut, New York - Entire State, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont) Local Coverage Determination (LCD): Molecular Pathology Procedures (L35000), Revision Effective Date for services performed on or after 10/01/2018.